Literature DB >> 3034616

The importance of primary cytomegalovirus infection in childhood cancer.

T Furukawa, Y Funamoto, S Ishida, H Kamiya.   

Abstract

Sixty-eight paediatric patients with malignant tumours or leukaemia were followed for signs of infection with human cytomegalovirus (HCMV) over 1 year. HCMV was isolated from 24 out of 68 patients at some point during the observation period; from urine in 14, from both urine and throat in 9 patients, and from throat alone in 1 patient. Previous antibody analysis indicated the presence of HCMV antibodies in 10 of the 24 virus-shedding patients, while 7 patients were seronegative and 7 undefined. Thus the incidence of reactivation appears to be higher than that of primary infection in these immunocompromised patients. The mean duration of virus shedding was 4.2 months in the primary infection group, 1.7 months in the reactivation group and 1.1 months in the undefined group. No difference in the incidence of HCMV-associated illness was observed between patients with leukaemia and those with malignant tumours. Clinical symptoms associated with HCMV infection (pneumonia (2), fever (6) and hepatitis (1)) were observed in all patients with primary infections and in only five patients with reactivated infection.

Entities:  

Mesh:

Year:  1987        PMID: 3034616     DOI: 10.1007/BF00647279

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  THE INCIDENCE OF INFECTION WITH CYTOMEGALOVIRUS IN A NORMAL POPULATION. A SEROLOGICAL STUDY IN GREATER LONDON.

Authors:  H STERN; S D ELEK
Journal:  J Hyg (Lond)       Date:  1965-03

2.  Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication.

Authors:  T Furukawa; A Fioretti; S Plotkin
Journal:  J Virol       Date:  1973-06       Impact factor: 5.103

3.  Prevalence of complement-fixing antibodies to cytomegalovirus in a semirural southern county.

Authors:  G R Monif; R J Hildebrandt; J M Weber
Journal:  Am J Obstet Gynecol       Date:  1970-10-01       Impact factor: 8.661

4.  Cytomegalovirus infection in childhood leukaemia.

Authors:  R N Sutton; C W Darby; S M Gumpel
Journal:  Br J Haematol       Date:  1971-04       Impact factor: 6.998

5.  Characteristics of a human diploid cell designated MRC-5.

Authors:  J P Jacobs; C M Jones; J P Baille
Journal:  Nature       Date:  1970-07-11       Impact factor: 49.962

6.  Recovery of cytomegalovirus from adults with neoplastic disease.

Authors:  C P Duvall; A R Casazza; P M Grimley; P P Carbone; W P Rowe
Journal:  Ann Intern Med       Date:  1966-03       Impact factor: 25.391

7.  HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients.

Authors:  G V Quinnan; N Kirmani; E Esber; R Saral; J F Manischewitz; J L Rogers; A H Rook; G W Santos; W H Burns
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

8.  Anticomplement immunofluorescence test that uses isolated fibroblast nuclei for detection of antibodies to human cytomegalovirus.

Authors:  L Mintz; R C Miner; A S Yeager
Journal:  J Clin Microbiol       Date:  1980-10       Impact factor: 5.948

9.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

10.  Primary infection with human cytomegalovirus: virus isolation from healthy infants and pregnant women.

Authors:  Y Numazaki; N Yano; T Morizuka; S Takai; N Ishida
Journal:  Am J Epidemiol       Date:  1970-04       Impact factor: 4.897

View more
  1 in total

1.  Beta-herpesviruses in febrile children with cancer.

Authors:  Stephanie Yee-Guardino; Kate Gowans; Belinda Yen-Lieberman; Pamela Berk; Debra Kohn; Fu-Zhang Wang; Lara Danziger-Isakov; Camille Sabella; Sarah Worley; Philip E Pellett; Johanna Goldfarb
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.